Abstract 211P
Background
Bladder cancer belongs to one of the top ten most common cancers in the world with approximately 550,000 cases annually. The general 5-year survival rate for people with bladder cancer is 77%. The overall 10-year survival rate is 70% and the overall 15-year survival rate is 65%. Low muscle mass is prevalent in these patients receiving chemotherapy. In this meta-analysis, we aim to assess the impact of low muscle mass on overall survival in bladder cancer patients undergoing chemotherapy.
Methods
A systematic review was performed according to PRISMA guidelines. A literature search using confidence method, was conducted by two independent reviewers on all of the studies that include low muscle mass in bladder cancer patients undergoing chemotherapy using Google Scholar, PubMed, and PubMed central databases. Outcome of interest in this study is the overall survival. Data synthesis and statistical analysis were carried out using Review Manager Software.
Results
A total of 4 studies were eligible for meta-analysis including a total of 370 bladder cancer patients undergoing chemotherapy. All of the studies were observational studies. Meta-analysis revealed that there are no association between low muscle mass and overall survival (HR 1.24; 95% CI 0.71-2.19; P< 0.45). The quality of this study was assessed with Newcastle Ottawa Scale (NOS) shows “good” quality in all included studies.
Conclusions
Our meta-analysis shows that low muscle mass is not associated with the overall survival of bladder cancer patients undergoing chemotherapy. Further study need evaluate in better patient selection and adjusting the confounder.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - Mutational landscape of gastric cancer (GC) in adolescents and young adults (AYA) in Asia from 2015-2019
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
154P - A multicenter, prospective study of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer
Presenter: Yi-Hui Tang
Session: e-Poster Display Session
155P - Surgical outcomes and technical performance of robotic versus laparoscopic total gastrectomy for gastric cancer: A prospective comparative study FUGES-014
Presenter: Hua-Gen Wang
Session: e-Poster Display Session
156P - Safety and feasibility of laparoscopic spleen-preserving splenic hilar lymphadenectomy during total gastrectomy for advanced proximal gastric cancer: A randomized clinical trial
Presenter: Jian-Xian Lin
Session: e-Poster Display Session
157P - Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
Presenter: Amy Prawira
Session: e-Poster Display Session
158P - A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX study): Final report
Presenter: Atsuo Takashima
Session: e-Poster Display Session
159P - Open surgery can improve the 3-year postoperative survival in some patients with advanced gastric cancer compared with laparoscopic surgery: A multicenter, propensity score matching, in-depth analysis
Presenter: Ze-Ning Huang
Session: e-Poster Display Session
160P - Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Ning Li
Session: e-Poster Display Session
161P - Adjuvant tegafur/gimeracil/oteracil (S-1) versus platinum-based chemotherapies for resectable gastric cancer: Real-world experience and a propensity score matching analysis
Presenter: Chih Chieh Yen
Session: e-Poster Display Session
162P - Evaluation of neutrophil/lymphocyte ratio (NLR) in monitoring anastomotic leakage after radical total gastrectomy for gastric cancer
Presenter: Ru-Hong Tu
Session: e-Poster Display Session